{"id":1006228,"date":"2026-09-28T08:37:02","date_gmt":"2026-09-28T12:37:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/"},"modified":"2026-09-28T08:37:02","modified_gmt":"2026-09-28T12:37:02","slug":"achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/","title":{"rendered":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SEATTLE and VANCOUVER, British Columbia, Sept.  28, 2026  (GLOBE NEWSWIRE) &#8212; Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.<\/p>\n<p>\n        <strong>CHEST 2026 Presentation Details<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial<\/li>\n<li style=\"margin-bottom:8pt\">Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope<\/li>\n<li style=\"margin-bottom:8pt\">Date\/Time: Tuesday, October 20, 2026, 2:09\u20132:13 p.m. MST<\/li>\n<li style=\"margin-bottom:8pt\">Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences<\/li>\n<li>Authors: Judith J. Prochaska, PhD, MPH, Stanford University; Neal L. Benowitz, MD, University of California, San Francisco; Dorothy K. Hatsukami, PhD, Masonic Cancer Center, University of Minnesota; Matthew E. Linley-Adams, Achieve Life Sciences; Mark L. Rubinstein, MD, Achieve Life Sciences; Nancy A. Rigotti, MD, Harvard Medical School<\/li>\n<\/ul>\n<p>The presentation will feature results from ORCA-OL, an open-label study that enrolled 475 adults who previously participated in the ORCA-2, ORCA-3 or ORCA-V1 trials and were actively smoking cigarettes and\/or vaping daily. Participants received cytisinicline 3 mg three times daily for 52 weeks with behavioral support. The analysis evaluated abstinence throughout the 52-week treatment period, including biochemically verified four-week sustained abstinence and seven-day point prevalence abstinence.<\/p>\n<p>For more information about the conference, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MWba-Z_Ewo6mVJyywTSxxLWZHBZDECaOsQyJeJAaF2fY8UBVJwW-UTgJTHEl6QYOi49iORyarPPeOdr9Ip3mY6Dc4JgJVMcG9217HICIfcTZx1aAb168Dz56INuzex1DyOud60Qyj-0GbV_7zC4MtyPbnzSwrDgWE8GxeC1rveSQr8UAnyByJVicW7LMY4GOo5coTRb-xDUkg1F2k17UMPghnbb-X0rEQra953Z4gns=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.chestnet.org\/learning-and-events\/events\/chest-annual-meeting<\/a>.<\/p>\n<p>\n        <strong>About Cytisinicline<\/strong><br \/>\n        <br \/>There are approximately 25 million adults in the United States who smoke combustible cigarettes.\u00b9 Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.\u00b2,\u00b3<\/p>\n<p>In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.\u00b9 In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.\u2074 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner\u2019s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.<\/p>\n<p>Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.<\/p>\n<p>\n        <strong>About Achieve Life Sciences, Inc.<\/strong><br \/>\n        <br \/>Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve\u2019s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the potential benefits of cytisinicline, the potential market for cytisinicline, and the Company\u2019s commercialization plans and readiness. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management\u2019s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve\u2019s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.<\/p>\n<p>\n        <strong>Achieve Contact<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Nicole Jones<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ckk5SpiLFFxHM5JRvMydxmE3m5gALdtEgDPiwjvsIuZI13kxbaNmKGIZyACkyBzDeIPeis958yOGwQkf_v_pGeHx_sV6zGHlxx_VBz7ZaoiCjsfZwUbPa_rl7ZRfRjXh4g2_ZUxNBbNTKLxkH0FfI3y9LRSBGp17Vd6VuDFGm0w8eRPk4454rHo41sxvA5Cj11_XS3OikKDT86aQycAx0R-DqJv1pvv67TE-4uUFbZQkL5J5kNgoqX6MbGwOJJe58Qn1ESdY-R12x5tvmo9DvVnqa2ZWP2Nein1z5y3SJfTFNKKyTwIRo4hqveKuI6pk\" rel=\"nofollow\" target=\"_blank\">ir@achievelifesciences.com<\/a><br \/>425-686-1510<\/p>\n<p>\n        <strong>References<\/strong><br \/>\n        <br \/>\u00b9Agaku I. Tobacco Product Use among U.S. Adults, 2023\u20132024, NEJM Evidence, doi: 10.1056\/EVIDpha2500339.<br \/>\u00b2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.<br \/>\u00b3U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.<br \/>\u2074Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, <em>Nicotine &amp; Tobacco Research<\/em>, 2026; ntag116, doi.org\/10.1093\/ntr\/ntag116.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDkwZTRiOWItOTYxZS00NjQ1LWI0NGQtYWI0NjBlZTA1OTFiLTEwMTU0MDItMjAyNi0wOS0yOC1lbg==\/tiny\/Achieve-Life-Sciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2026 Presentation Details Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope Date\/Time: Tuesday, October 20, 2026, 2:09\u20132:13 p.m. MST Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences Authors: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006228","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2026 Presentation Details Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope Date\/Time: Tuesday, October 20, 2026, 2:09\u20132:13 p.m. MST Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences Authors: &hellip; Continue reading &quot;Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-28T12:37:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026\",\"datePublished\":\"2026-09-28T12:37:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/\"},\"wordCount\":815,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/\",\"name\":\"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\",\"datePublished\":\"2026-09-28T12:37:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/","og_locale":"en_US","og_type":"article","og_title":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk","og_description":"SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona. CHEST 2026 Presentation Details Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope Date\/Time: Tuesday, October 20, 2026, 2:09\u20132:13 p.m. MST Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences Authors: &hellip; Continue reading \"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-28T12:37:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026","datePublished":"2026-09-28T12:37:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/"},"wordCount":815,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/","name":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=","datePublished":"2026-09-28T12:37:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY2NCM3ODY1NzIwIzIwMDM4Mjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achieve-life-sciences-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006228"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006228\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}